ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ekso Bionics Hlds

Inhibikase Therapeutics

ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.

Best Momentum Stocks to Buy for January 31st

Anavex Life Sciences

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

New Strong Buy Stocks for January 31st

Canadian Imperial Bank of Commerce

Turtle Beach

ADMA, CM and HEAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.

Best Momentum Stocks to Buy for January 24th

Potbelly

ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.

New Strong Buy Stocks for January 24th

The consensus price target hints at a 27.1% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 27.09% Upside in Adma Biologics (ADMA): Here's What You Should Know

ADMA Biologics enters 2024 on quite a roll and the stock should continue to do well going forward. The company has recently completed the build of its plasma collection network, turned the corner on profitability, and redid its credit facility in a positive way. Why momentum for ADMA Biologics should continue in 2024 is highlighted below.

ADMA Biologics: On A Roll Entering 2024

Arcutis Biotherapeutics

ADMA and ARQT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.

Best Momentum Stocks to Buy for January 11th (Revised)

Phreesia Inc

ADMA, ARQT and PHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.

Best Momentum Stocks to Buy for January 11th

OptimizeRx Corp

Royal Philips

ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.

New Strong Buy Stocks for January 11th

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjusted EBITDA ( 1) Expected to be $85 Million Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance During 2024 RAMSEY, N.J. and BOCA RATON, Fla.

ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update

Does Adma Biologics (ADMA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Adma Biologics (ADMA) is a Great Choice

From a technical perspective, ADMA Biologics Inc (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Should You Buy Adma Biologics (ADMA) After Golden Cross?

New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla.

ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management

Signifies the Successful Fulfillment of BIVIGAM's Post Marketing Commitments as Part of the Original BLA Approval

ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older

The Food and Drug Administration approved the company's tenth plasma-collection facility. This is located in Maryland.

Why Adma Biologics Stock Crushed the Market on Friday

FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficiency FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficiency

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD

The biotech published its third-quarter results after market close on Wednesday. Revenue growth was strong, while the bottom line did a nice flip into the black.

Why Adma Biologics Was Trouncing the Market Today

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Skyler Bloom - Head, Business Development & Corporate Strategy Adam Grossman – President & CEO Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Kristen Kluska - Cantor Fitzgerald Anthony Petrone - Mizuho Group Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2023 Financial Results and Corporate Update Conference Call on Wednesday, November 8, 2023. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) Q3 2023 Earnings Call Transcript

3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to $74.2 Million 3Q2023 Adjusted EBITDA ( 1) Grew to $12.7 Million, a 98% Q-o-Q Increase FY2023 Total Revenue Now Expected to Exceed $250 Million, Increased from $240 Million Adjusted EBITDA and Net Income Growth Expected Over the Remainder of 2023 and Beyond FY2024 and 2025 Total Revenue Guidance Increased to More than $290 Million and $335 Million, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.

ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update

ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023

In the most recent trading session, Adma Biologics (ADMA) closed at $3.44, indicating a +1.78% shift from the previous trading day.

Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

ADMA grew revenue and trimmed its losses compared to the same quarter a year ago. The company increased revenue guidance for 2023, 2024, and 2025.

Why Shares of ADMA Biologics Are Climbing Thursday

Adma Biologics (ADMA) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million Adjusted EBITDA Growth Expected Over the Remainder of 2023 FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.

News for ADMA Biologics Stock (ADMA)